FOLFOX/FOLFIRI Containing Levofolinic Acid (Zuoyu ®) in the Treatment of Unresectable or Metastatic Colorectal Cancer

China Medical University, China

Status and phase

Enrolling

Phase 2

Conditions

Unresectable or Metastatic Colorectal Cancer

Treatments

Drug: FOLFOX/FOLFIRI

Study type

Interventional

Funder types

Other

Identifiers

NCT05797883

HL-ZY-002

Details and patient eligibility

About

To observe and evaluate the efficacy and safety of FOLFOX/FOLFIRI± target-directed regimen containing Levofolinic Acid (Zuoyu ®) in first-line treatment of unresectable or metastatic colorectal cancer

Enrollment

30 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Male or female, ≥18 years old;
Patients with histopathologically confirmed unresectable or metastatic colorectal cancer who have not previously received chemotherapy or targeted therapy for unresectable or metastatic lesions;
Have at least one measurable lesion according to RECIST 1.1 standards;
ECOG PS score: 0-2;
Expected survival greater than 3 months;
Routine blood routine, liver and kidney function, electrocardiogram and other routine tests were basically normal, no contraindications of chemotherapy;
The subjects voluntarily joined the study, signed the informed consent, had good compliance, and cooperated with follow-up visits;
Researchers believe treatment can benefit.

Exclusion criteria

A proven allergy to the test drug and/or its excipients;
Pregnant or lactating women;
Patients judged by the investigator to be unsuitable for inclusion in this study;